FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 |
|---------------------|-----------|
| Estimated average b | ourden |
| hours per response. | 0.5 |

| | Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
|--|--|
|--|--|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person [*] Hack Andrew A. F. | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>DYNAVAX TECHNOLOGIES CORP</u> [DVAX] | | | | | | | | | 5. Relationship of Repor (Check all applicable) X Director | | | 10% Owner | |
|---|--|--|--------------------|--|---|---|--------|---------------|--|-----------|------------------------------------|---|--|--|---|---------|--|--|
| (Last) (First) (Middle) C/O BAIN CAPITAL LIFE SCIENCES | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 08/08/2023 | | | | | | | | | belov | cer (give title w) | | belo | er (specify w) |
| INVESTORS | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | |
| LLC, 200 CLARENDON STREET | | | | | | | | | | | | - | X Form filed by One Reporting Person | | | | | |
| (Street) | | | | | | | | | | | | | | Form Perse | | More th | ian One I | Reporting |
| BOSTO | N M. | A 0. | 2116 | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | | |
| (City) (State) (Zip) | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yet) | | | Execution Date, | | on Date, | Transaction Dispo Code (Instr. 5) | | Disposed Of (| es Acquired (A) c Of (D) (Instr. 3, 4 | | Beneficially Owned Following | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | Coc | de | v | Amount | (A) or (D) | Price | Reported Transact (Instr. 3 a | ion(s) | | | | |
| Common Stock 08/0 | | | 3/08/2023 | 23 | | | | s | | 1,500,000 | D | \$14.39 | 915,000 | | | | See footnotes ⁽¹⁾ (2) | |
| Common Stock | | | | | | | | | | | | | 10,7 | 714 | | D | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | ate Execution Date | | | 4. Transaction Code (Instr. 8) | | r E | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | | | 10. Owners Form: Direct (I or Indire (I) (Instr | Beneficia O) Ownershi ect (Instr. 4) |
| | | | | | Code | v | (A) (I | | Date Exerc | isable | Expiration Date | | Amount or Number of Shares | | | | | |

Explanation of Responses:

1. Represents shares of common stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

2. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Partner of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

<u>/s/ Andrew Hack</u>

** Signature of Reporting Person Date

08/10/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.